- Home
- XTKG vs CTXR Comparison
XTKG vs CTXR Comparison
Compare XTKG & CTXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XTKG
- CTXR
- Stock Information
- Founded
- XTKG 1997
- CTXR 2007
- Country
- XTKG Singapore
- CTXR United States
- Employees
- XTKG N/A
- CTXR N/A
- Industry
- XTKG
- CTXR Biotechnology: Pharmaceutical Preparations
- Sector
- XTKG
- CTXR Health Care
- Exchange
- XTKG NYSE
- CTXR Nasdaq
- Market Cap
- XTKG 16.3M
- CTXR 14.6M
- IPO Year
- XTKG 2019
- CTXR N/A
- Fundamental
- Price
- XTKG $1.55
- CTXR $1.58
- Analyst Decision
- XTKG
- CTXR Strong Buy
- Analyst Count
- XTKG 0
- CTXR 3
- Target Price
- XTKG N/A
- CTXR $53.00
- AVG Volume (30 Days)
- XTKG 106.9K
- CTXR 6.8M
- Earning Date
- XTKG 07-07-2025
- CTXR 08-11-2025
- Dividend Yield
- XTKG N/A
- CTXR N/A
- EPS Growth
- XTKG N/A
- CTXR N/A
- EPS
- XTKG N/A
- CTXR N/A
- Revenue
- XTKG $11,611,442.00
- CTXR N/A
- Revenue This Year
- XTKG N/A
- CTXR N/A
- Revenue Next Year
- XTKG N/A
- CTXR N/A
- P/E Ratio
- XTKG N/A
- CTXR N/A
- Revenue Growth
- XTKG N/A
- CTXR N/A
- 52 Week Low
- XTKG $0.53
- CTXR $0.65
- 52 Week High
- XTKG $11.60
- CTXR $26.25
- Technical
- Relative Strength Index (RSI)
- XTKG 49.51
- CTXR 68.44
- Support Level
- XTKG $1.36
- CTXR $0.76
- Resistance Level
- XTKG $2.24
- CTXR $1.45
- Average True Range (ATR)
- XTKG 0.23
- CTXR 0.31
- MACD
- XTKG -0.03
- CTXR 0.06
- Stochastic Oscillator
- XTKG 22.22
- CTXR 47.63
About XTKG X3 HOLDINGS CO LTD
X3 Holdings Co Ltd is company which is responsible for globally providing of Technology Solutions and Services across Diverse Industries. It generates revenue from service lines: Application development services; Consulting and technical support services; Subscription services; Trading; and Others, of which maximum revenue is derived from Application development services. Geographically, all of the company's revenue is derived from PRC.
About CTXR Citius Pharmaceuticals Inc.
Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. The company is currently advancing four proprietary product candidates namely, LYMPHIR for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections, Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries, Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids, and others.